@Amgen thinks so, releases @Nature phase 1 study of AMG 133 (maridebart cafraglutide) a combination of GIPR antagonist monoclonal anti- body and two GLP-1 agonist peptides Safe, tolerable with dose-dependent weight loss maintained to 150 days go.nature.com/3HUHBjB Join the conversation
Bajaj JS, Fagan A, White MB, et al
The skin there should be soft and pinchable
Most athletes tolerate it extremely well
Future directions The melanocortin system is well established as a key regulator of metabolic processes, leading many pharmaceutical and biotech companies to target these receptors, particularly MC4R, for their anti-obesity potential
At the end of the study, the scientists found that a very low-calorie diet and the combination of a very low-calorie diet and semaglutide led to significantly greater reductions in body weight and fat mass than semaglutide alone